Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+12.56%
+0.83%
+4.59%
-5.10%
AMGN
Amgen
$300.60
Chart
$272.13 (+10.46%)
$291.09 (+3.27%)
$306.38 (-1.89%)
$331.29 (-9.26%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+12.56%
+0.83%
+4.59%
-5.10%
AMGN
Amgen
Current Price
$300.60
Hold
Login to view Amgen (AMGN) recommendation from the last 90 days from financial news and social media.
Chart
$272.13 (+10.46%)
$291.09 (+3.27%)
$306.38 (-1.89%)
$331.29 (-9.26%)
AMGN Latest Analysis
This House of Representative Just Bought Up To $30K In Amgen Stock. A report on July 9 2025 shows that Representative Cliff Bentz from Oregon purchase stock in Amgen (NASDAQ:) valued between $2002 and $30000. According to the July filing the transaction occurred on June 6 2025.At the time of writing Amgen shares are trading down 0.11% at $296.19.Over the previous three years Cliff Bentz conducted 5 trades totaling more than $254 thousand. The largest of these were in Amgen and Procter &. Gamb
Today
Noteworthy Tuesday Option Activity: AMGN DJT AR. Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Amgen Inc (Symbol: AMGN) where a total of 15814 contracts have traded so far representing approximately 1.6 million underlying shares. That amounts to about 55.9% of
Tue Jul 1, 2025
Paroxysmal Nocturnal Hemoglobinuria Market Set for Robust Growth During the Forecast Period (2025–2034) Owing to the Advancements in Complement Inhibitor Therapies | DelveInsight. Paroxysmal Nocturnal Hemoglobinuria Market Set for Robust Growth During the Forecast Period (2025–2034) Owing to the Advancements in Complement Inhibitor Therapies |. DelveInsight The paroxysmal nocturnal hemoglobinuria market is witnessing robust growth driven by increasing disease awareness improved diagnostics a
Tue Jul 1, 2025
Amgens Gastric Cancer Drug Improves Survival In Phase 3 Notes Ocular Side Effects. ) on Monday released data from the Phase 3 FORTITUDE-101 trial of first-line bemarituzumab plus chemotherapy (mFOLFOX6).The study met its primary endpoint of overall survival (OS) at a .Bemarituzumab plus chemotherapy demonstrated astatistically significant and clinically meaningful improvement in OS as compared toplacebo plus chemotherapy for unresectable locally advanced ormetastatic gastric or gastroesophageal
Mon Jun 30, 2025
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?. Amgen aims to challenge obesity drug leaders with MariTide a potential monthly treatment now in late-stage trials.
Fri Jun 27, 2025
Analyst Views Mixed As Amgens Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues. ) on Monday the full results from Part 1 of the Phase 2 study of .In the Phase 2 study MariTide demonstrated up to ~20% average weight loss in people living with obesity without Type 2 diabetes (T2D) compared with 2.6% in the placebo arm and up to ~17% average weight loss in people living with obesity with T2D compared with 1.4% in the placebo arm per the efficacy estimand.Weight loss had not pla
Tue Jun 24, 2025
Where Amgen Stands With Analysts. Across the recent three months 8 analysts have shared their insights on Amgen (NASDAQ:) expressing a variety of opinions spanning from ish to bearish.In the table below you'.ll find a summary of their recent ratings revealing the shifting sentiments over the past 30 days and comparing them to the previous months.0260000100000000230000200Providing deeper insights analysts have established 12-month price targets indicating an average target of $310.62 along wi
Tue Jun 24, 2025
Amgen stock maintains Overweight rating at Piper Sandler despite GI data.
Tue Jun 24, 2025
Amgen Inc. (AMGN) Presents at Special Call (IR Call) Conference Transcript.
Tue Jun 24, 2025
Amgen falls despite positive weight loss trial results.
Mon Jun 23, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
AMGN Stock trends
AMGN Stock performance
AMGN Stock analysis
AMGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings